BioCryst nods goalward to pharma partner, but M&A gets red card
This article was originally published in Scrip
BioCryst Pharmaceuticals believes it has a shot at the competitive gout market, based on positive Phase IIb data from the extension study for its novel oral drug ulodesine (BCX4208), but it needs a pharmaceutical partner to finish off the move.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.